Roche fumes as NICE releases 'perverse' guidance on second-line Tarceva
This article was originally published in Scrip
Executive Summary
NICE has released draft guidance reversing its 2008 decision to allow clinicians to use Roche's Tarceva (erlotinib) as a second-line treatment for non-small cell lung cancer on the NHS. Roche called the new guidance "perverse" and warned that it will leave some cancer patients with no treatment alternatives.